Development of Therapy Approach in Patient with Chronic Granulocity Leukemia: Case Report

1. Spiers AS. Clinical manifestations of chronic granulocytic leukemia. Semin Oncol. 1995 Aug;22(4):380-95. Search in Google Scholar

2. Saußele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015 Apr;94 Suppl 2:S159-65. doi: 10.1007/s00277-015-2324-0.10.1007/s00277-015-2324-025814082 Search in Google Scholar

3. Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015 Jun;6(6):403-12. doi: 10.1007/s13238-015-0143-7.10.1007/s13238-015-0143-7444481025749979 Search in Google Scholar

4. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010 Oct;47(4):302-11. doi: 10.1053/j.seminhematol.2010.07.001.10.1053/j.seminhematol.2010.07.00120875546 Search in Google Scholar

5. https://www.cancer.gov/publications/cancerterms/def/chronic-granulocytic-leukemia Search in Google Scholar

6. Eden RE, Coviello JM. Cancer, Leukemia, Myelogenous, Chronic (CML, Chronic Granulocytic Leukemia). 2018 Oct 27. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-Available from http://www.ncbi.nlm.nih.gov/books/NBK531459/ Search in Google Scholar

7. Shao X, Chen D, Xu P, Peng M, Guan C, Xie P, Yuan C, Chen B. Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. Medicine (Baltimore). 2018 Nov;97(44):e12949. doi: 10.1097/MD. 0000000000012949. Search in Google Scholar

8. Kuan JW, Su AT, Leong CF, Osato M, Sashida G. Systematic review of pre-clinical chronic myeloid leukaemia. Int J Hematol. 2018 Nov;108(5):465-484. doi: 10.1007/s12185-018-2528-x.10.1007/s12185-018-2528-x30218276 Search in Google Scholar

9. Marchetti M. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical view. Expert Rev Pharmacoecon Outcomes Res. 2017 Oct;17(5):469-480. doi: 10.1080/14737167.2017.1366858.10.1080/14737167.2017.136685828796569 Search in Google Scholar

10. Rajpal S, Nampoothiri RV, Sreedharanunni S, Parihar M, Malhotra P, Varma N. Granulocytic dysplasia: an indicator of clonal evolution in patients with chronic myeloid leukemia. Blood Res. 2018 Jun;53(2):180-181. doi: 10.5045/br.2018.53.2.180.10.5045/br.2018.53.2.180602158029963531 Search in Google Scholar

11. Bhatia R. Novel approaches to therapy in CML. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):115-120. doi: 10.1182/asheducation-2017.1.1 15.10.1182/asheducation-2017.1.1614252729222231 Search in Google Scholar

12. Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e71-e73. doi: 10.1016/j.clml.2017.09.004.10.1016/j.clml.2017.09.00429032022 Search in Google Scholar

13. Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi:m10.1158/1078-0432.CCR-17-0957.10.1158/1078-0432.CCR-17-095728939746 Search in Google Scholar

14. Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase ½ study. Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9.10.1007/s12185-017-2238-928444644 Search in Google Scholar

15. Fischer JT, Ho AD, Wilhelm M, Goebeler ME, et al. German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281.10.1038/leu.2015.281477777426464170 Search in Google Scholar

16. Jiang Q, Zhao D, Jin J, Wu D, Meng F, Hu J, Liu B, DU X, Liu T, Li Y, Hou M, Han X, Shen Z, Ma J. [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):651-5. doi: 10.3760/cma.j.issn.0253-2727.20 15.08.005. Search in Google Scholar

17. Hochhaus A, Rosti G, Cross NC, Steegmann JL, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270.10.1038/leu.2015.270470542526437782 Search in Google Scholar